When we assessed p-PERK and p-eIF2α across the olfactory regions in AD cases with different Braak stages of tau pathology, we found low grade (stage III-IV) AD cases had equivalent amounts of UPR activation to high grade (stage V-VI) AD cases. This evidence concerns the gene MAPT and Alzheimer disease.